A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 3

Conditions: HIV Pre-Exposure Prophylaxis; Human Immunodeficiency Virus (HIV)

Treatments: Drug: Emtricitabine/tenofovir disoproxil (FTC/TDF); Drug: MK-8527; Drug: Placebo matched to FTC/TDF; Drug: Placebo matched to MK-8527

Study type: Interventional

Funder types: Industry

Identifiers

NCT07071623

MK-8527-010 (Other Identifier)

8527-010

Details and patient eligibility

About

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

The goals of this study are to learn:

• If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day
• About the safety of MK-8527 and if people tolerate it

Enrollment: 4,580 estimated patients

Sex: Female

Ages: 16 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Is confirmed Human Immunodeficiency Virus (HIV)-uninfected based on negative HIV-1/HIV-2 test results
• Has been sexually active (2 vaginal intercourse encounters with cisgender male individual(s) within the last 3 months)
• Was assigned female sex at birth and is cisgender.
• Weighs ≥35 kg

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• Has hypersensitivity or other contraindication to any component of the study interventions
• Has evidence of acute or chronic hepatitis B infection
• Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
• Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time
• Is receiving or is anticipated to require any prohibited therapies from 30 days prior to Day 1 through the study duration
• Has received an HIV vaccine at any time (ie, through past participation in an investigational clinical study) or monoclonal antibodies to HIV within 12 months before Day 1

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

4,580 participants in 2 patient groups

MK-8527 + Placebo to FTC/TDF

Experimental group

Description:

Participants will receive 11 mg MK-8527 once monthly (QM) and placebo matched to Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) once daily (QD) for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

Treatment:

Drug: Placebo matched to FTC/TDF

Drug: MK-8527

FTC/TDF + Placebo to MK-8527

Active Comparator group

Description:

Participants will receive 200 mg FTC/245 mg TDF QD and placebo matched to MK-8527 QM for up to approximately 2 years. Participants will then receive open-label 200 mg FTC/245 mg TDF QD for an additional 28 days.

Treatment:

Drug: Placebo matched to MK-8527

Drug: Emtricitabine/tenofovir disoproxil (FTC/TDF)